U.S. Food and Drug Administration Approves Duvelisib (COPIKTRA) for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
New York, NY – The U.S. Food and Drug Administration (FDA) announced it has approved the use of duvelisib (COPIKTRA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after…